← Leaderboards
Sandra Orsulic
Massachusetts General Hospital
$4,151,521
Attributed
$4,151,521
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $590.6K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,151,521 · 3
VA$0 · 2
By mechanism
R01$3,733,920 · 2
R21$417,601 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Iain A. Drummond$18,307,587
- Katia Georgopoulos$27,357,145
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryGenesMalignant NeoplasmsCellsMalignant Breast NeoplasmTumor GrowthTumorCancer CellMolecularMouse ModelIn VivoAffectEventEquilibriumSignal TransductionAreaFibroblastsTumor MicroenvironmentOvarian NeoplasmTumor ProgressionOvarianNeoplasm MetastasisLesionOvarian Serous Adenocarcinoma
Grant awards (21)
Precancer Niche Formation in the Fallopian Tube$0
I01 · FY2024 · VA · contact PI
BCCMA: Overcoming chemoresistance in ovarian cancer: Identification and validation of biomarkers and targetable drivers of platinum resistance$0
I01 · FY2024 · VA · contact PI
Precancer Niche Formation in the Fallopian Tube$0
I01 · FY2023 · VA · contact PI
BCCMA: Overcoming chemoresistance in ovarian cancer: Identification and validation of biomarkers and targetable drivers of platinum resistance$0
I01 · FY2023 · VA · contact PI
Precancer Niche Formation in the Fallopian Tube$0
I01 · FY2022 · VA · contact PI
Precancer Niche Formation in the Fallopian Tube$0
I01 · FY2021 · VA · contact PI
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies$356,850
R01 · FY2020 · CA · contact PI
Precancer Niche Formation in the Fallopian Tube$0
I01 · FY2020 · VA · contact PI
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies$388,303
R01 · FY2019 · CA · contact PI
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies$103,452
R01 · FY2019 · CA · contact PI
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies$400,313
R01 · FY2018 · CA · contact PI
Cancer-Associated Fibroblasts Alter the Composition of B Cells I Solid Malignancies - Diversity Supplement$106,651
R01 · FY2018 · CA · contact PI
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies$400,313
R01 · FY2017 · CA · contact PI
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies$400,313
R01 · FY2016 · CA · contact PI
(PQA3) Why is Ovarian Cancer Primarily a Disease of Postmenopausal Women$190,313
R21 · FY2016 · CA · contact PI
(PQA3) Why is Ovarian Cancer Primarily a Disease of Postmenopausal Women$227,288
R21 · FY2015 · CA · contact PI
characterization of ovarian cancer in a mouse model$315,864
R01 · FY2008 · CA · contact PI
Molecular characterization of ovarian cancer in a mouse model$305,173
R01 · FY2007 · CA · contact PI
characterization of ovarian cancer in a mouse model$314,287
R01 · FY2006 · CA · contact PI
characterization of ovarian cancer in a mouse model$321,850
R01 · FY2005 · CA
characterization of ovarian cancer in a mouse model$320,551
R01 · FY2004 · CA